Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma (real-world observational study)
ChiCTR2600117901Phase 4Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Progression-free survival. Started Jan 2026; status: recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2600117901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117901.